Astrid Koehler

3.0k total citations
15 papers, 577 citations indexed

About

Astrid Koehler is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Astrid Koehler has authored 15 papers receiving a total of 577 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Astrid Koehler's work include HER2/EGFR in Cancer Research (5 papers), Melanoma and MAPK Pathways (3 papers) and Breast Cancer Treatment Studies (3 papers). Astrid Koehler is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Melanoma and MAPK Pathways (3 papers) and Breast Cancer Treatment Studies (3 papers). Astrid Koehler collaborates with scholars based in Switzerland, Germany and United States. Astrid Koehler's co-authors include Anton Belousov, Semiglazov Vf, Milvia Zambetti, Giampaolo Bianchini, Aleix Prat, W. Eiermann, Maggie C.U. Cheang, José Baselga, Jonathan Deutsch and Geoffrey I. Shapiro and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Astrid Koehler

15 papers receiving 566 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Astrid Koehler Switzerland	10	330	316	166	75	69	15	577
Laura Vízkeleti Hungary	14	367 1.1×	365 1.2×	180 1.1×	45 0.6×	91 1.3×	33	622
Davide Torti Italy	12	304 0.9×	418 1.3×	137 0.8×	77 1.0×	116 1.7×	17	677
Steve Guerrero United States	5	221 0.7×	431 1.4×	128 0.8×	47 0.6×	86 1.2×	6	621
P.N. Munster United States	12	336 1.0×	307 1.0×	79 0.5×	72 1.0×	119 1.7×	18	584
Eugenia R. Zanella Italy	7	399 1.2×	313 1.0×	213 1.3×	119 1.6×	113 1.6×	14	668
Heiko Maacke Switzerland	14	493 1.5×	656 2.1×	127 0.8×	92 1.2×	152 2.2×	21	902
Ingrid Lebigot France	8	286 0.9×	248 0.8×	191 1.2×	74 1.0×	76 1.1×	8	543
Andrew Elliott United States	10	260 0.8×	191 0.6×	89 0.5×	64 0.9×	146 2.1×	99	483
Saori Fujiwara Japan	18	268 0.8×	492 1.6×	384 2.3×	73 1.0×	122 1.8×	34	845
Edward Clark United States	6	468 1.4×	330 1.0×	279 1.7×	62 0.8×	85 1.2×	6	764

Countries citing papers authored by Astrid Koehler

Since Specialization

Citations

This map shows the geographic impact of Astrid Koehler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Astrid Koehler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Astrid Koehler more than expected).

Fields of papers citing papers by Astrid Koehler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Astrid Koehler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Astrid Koehler. The network helps show where Astrid Koehler may publish in the future.

Co-authorship network of co-authors of Astrid Koehler

This figure shows the co-authorship network connecting the top 25 collaborators of Astrid Koehler. A scholar is included among the top collaborators of Astrid Koehler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Astrid Koehler. Astrid Koehler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Brucker, Cosima, Thomas Decker, PA Fasching, et al.. (2023). 441P Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study. Annals of Oncology. 34. S366–S367. 1 indexed citations

Marmé, Frederik, Cosima Brucker, Thomas Decker, et al.. (2023). 411P Therapy management and safety of 1st-line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA)). Annals of Oncology. 34. S355–S356. 1 indexed citations

Boult, Jessica K.R., Markus Thomas, Astrid Koehler, et al.. (2016). Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling. British Journal of Cancer. 115(6). 691–702. 14 indexed citations

Stubenrauch, Kay, et al.. (2014). An immunodepletion procedure advances free angiopoietin-2 determination in human plasma samples during anti-cancer therapy with bispecific anti-Ang2/VEGF CrossMab. Journal of Pharmaceutical and Biomedical Analysis. 102. 459–467. 5 indexed citations

Prat, Aleix, Giampaolo Bianchini, Marlène Thomas, et al.. (2014). Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study. Clinical Cancer Research. 20(2). 511–521. 158 indexed citations

Hidalgo, Manuel, Christophe Le Tourneau, Christophe Massard, et al.. (2014). Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2525–2525. 11 indexed citations

Tolcher, Anthony W., Wells A. Messersmith, Stanislaw M. Mikulski, et al.. (2012). Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors. Journal of Clinical Oncology. 30(19). 2348–2353. 207 indexed citations

Sosman, Jeffrey A., Anna C. Pavlick, Lynn M. Schuchter, et al.. (2012). Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAF^V600Emelanoma.. Journal of Clinical Oncology. 30(15_suppl). 8503–8503. 19 indexed citations

Bianchini, Giampaolo, Aleix Prat, Marlene Pickl, et al.. (2011). Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis.. Journal of Clinical Oncology. 29(15_suppl). 529–529. 16 indexed citations

10.

McArthur, Grant A., Antoni Ribas, Paul B. Chapman, et al.. (2011). Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation–positive metastatic melanoma patients (pts).. Journal of Clinical Oncology. 29(15_suppl). 8502–8502. 28 indexed citations

11.

Lacouture, Mario E., Paul B. Chapman, Antoni Ribas, et al.. (2011). Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.. Journal of Clinical Oncology. 29(15_suppl). 8520–8520. 15 indexed citations

12.

Pardo, P. Gómez, Aleix Prat, Giampaolo Bianchini, et al.. (2011). PAM50 intrinsic subtyping and pathologic responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer.. Journal of Clinical Oncology. 29(15_suppl). 554–554. 6 indexed citations

13.

Koehler, Astrid, Leoni A. Kunz‐Schughart, Ferdinand Hofstaedter, & Wolfgang Dietmaier. (2007). Multiple Molecular Analyses From Minimal Cell Quantities by Sequential Isolation and Preamplification of DNA and RNA. Diagnostic Molecular Pathology. 16(3). 141–146. 1 indexed citations

14.

Koehler, Astrid, Frauke Bataille, Petra Ruemmele, et al.. (2004). Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage. The Journal of Pathology. 204(1). 65–74. 80 indexed citations

15.

Koehler, Astrid, et al.. (1998). Successful treatment of disseminated coccidioidomycosis with amphotericin B lipid complex. Journal of Infection. 36(1). 113–115. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact